Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Zhu X, Morgenlander WR, Brown DM, Eby Y, Morsheimer M, Odim J, Bagnasco SM, Rana MM, Florman SS, Friedman-Moraco RJ, Stock PG, Gilbert AJ, Mehta[...]
Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, Chen L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade[...]
Stephens AV, Thauland TJ, Whitehill GD, Garcia-Lloret MI, Butte MJ. Immunomodulation in the Treatment of Disseminated Coccidioidomycosis. Clin Infect Dis. 2026 Mar 4:ciag036. doi: 10.1093/cid/ciag036.[...]